Liver fibrosis results from chronic damages together with an accumulation of extracellular matrix, and no specific medical therapy is approved for that until now. Due to liver metabolic capacity for drugs, the fragility of drugs, and the presence of insurmountable physiological obstacles in the way of targeting, the development of efficient drug delivery systems for anti-fibrotics seems vital. We have explored articles with a different perspective on liver fibrosis over the two decades, then collected and summarized the information by providing corresponding in vitro and in vivo cases. We have discussed the mechanism of hepatic fibrogenesis with different ways of fibrosis induction in animals. Furthermore, the critical chemical and herbal anti-fibrotics, biological molecules such as micro-RNAs, siRNAs, and growth factors, which can affect cell division and differentiation, are mentioned. Likewise, drug and gene delivery and therapeutic systems on in vitro and in vivo models are summarized in the data tables. This review article enlightens recent advances in emerging drugs and nanocarriers and represents perspectives on targeting strategies employed in liver fibrosis treatment.

肝纤维化是由慢性损伤和细胞外基质积累引起的，迄今为止还没有批准针对此的特定药物治疗方法。由于肝脏对药物的代谢能力、药物的脆弱性以及靶向方式存在难以克服的生理障碍，开发高效的抗纤维化药物递送系统显得至关重要。我们探索了二十年来对肝纤维化具有不同视角的文章，然后通过提供相应的 体外 和 体内 案例来收集和总结信息。我们已经通过不同的动物纤维化诱导方式讨论了肝纤维化的机制。此外，还提到了可以影响细胞分裂和分化的关键化学和草药抗纤维化、生物分子（例如 micro-RNA、siRNA 和生长因子）。 同样，数据表中总结了体外 和 体内模型上的药物和基因递送以及治疗系统 。这篇综述文章启发了新兴药物和纳米载体的最新进展，并代表了肝纤维化治疗中采用的靶向策略的观点。